Back to Search Start Over

Use of levothyroxine for euthyroid, thyroid antibody positive women with infertility: Analyses of aggregate data from a survey of European thyroid specialists (Treatment of Hypothyroidism in Europe by Specialists: An International Survey).

Authors :
Negro R
Žarković M
Attanasio R
Hegedüs L
Nagy EV
Papini E
Akarsu E
Alevizaki M
Ayvaz G
Bednarczuk T
Beleslin BN
Berta E
Bodor M
Borissova AM
Boyanov M
Buffet C
Burlacu MC
Ćirić J
Cohen CA
Díez JJ
Dobnig H
Fadeyev V
Field BCT
Fliers E
Führer D
Galofré JC
Hakala T
Jan J
Kopp P
Krebs M
Kršek M
Kužma M
Leenhardt L
Luchytskiy V
Puga FM
McGowan A
Melo M
Metso S
Moran C
Morgunova T
Niculescu DA
Perić B
Planck T
Poiana C
Robenshtok E
Rosselet PO
Ruchala M
Riis KR
Shepelkevich A
Tronko M
Unuane D
Vardarli I
Visser E
Vryonidou A
Younes YR
Perros P
Source :
Clinical endocrinology [Clin Endocrinol (Oxf)] 2024 Aug; Vol. 101 (2), pp. 180-190. Date of Electronic Publication: 2024 Jun 10.
Publication Year :
2024

Abstract

Objectives: The use of levothyroxine (LT4) treatment aiming to improve fertility in euthyroid women with positive thyroid peroxidase antibodies (TPOAb) is not supported by the available evidence. The aim of the study was to document the use of LT4 by European thyroid specialists in such patients.<br />Design: The data presented derive from Treatment of Hypothyroidism in Europe by Specialists, an International Survey (THESIS), a questionnaire conducted between 2019 and 2021 to document the management of hypothyroidism by European thyroid specialists. Here, we report the aggregate results on the use of LT4 in infertile, euthyroid women with positive TPOAb.<br />Results: A total of 2316/5406 (42.8%) respondents stated that LT4 may be indicated in TPOAb positive euthyroid women with infertility. The proportion of those replying positively to this question varied widely across different countries (median 39.4, range 22.9%-83.7%). In multivariate analyses males (OR: 0.8; CI: 0.7-0.9) and respondents >60 years (OR: 0.7; 0.6-0.8) were the least inclined to consider LT4 for this indication. Conversely, respondents managing many thyroid patients ("weekly" [OR: 1.4; CI: 1.0-1.9], "daily" [OR: 1.8; CI: 1.3-2.4]) and practicing in Eastern Europe (OR: 1.5; CI: 1.3-1.9) were most likely to consider LT4.<br />Conclusions: A remarkably high number of respondents surveyed between 2019 and 2021, would consider LT4 treatment in TPOAb positive euthyroid women with infertility. This view varied widely across countries and correlated with sex, age and workload, potentially influencing patient management. These results raise concerns about potential risks of overtreatment.<br /> (© 2024 John Wiley & Sons Ltd.)

Details

Language :
English
ISSN :
1365-2265
Volume :
101
Issue :
2
Database :
MEDLINE
Journal :
Clinical endocrinology
Publication Type :
Academic Journal
Accession number :
38856700
Full Text :
https://doi.org/10.1111/cen.15099